BETH ISRAEL DEACONESS MEDICAL CENTER
Androgen Receptor Action in Castration Resistant Prostate Cancer
Androgen Receptor Action in Castration Resistant Prostate Cancer is a funding opportunity from BETH ISRAEL DEACONESS MEDICAL CENTER, up to 1990456, closing August 31, 2030.
Aug 31, 2030
(1492d left)Overview
Project Summary A central hypothesis that drove the studies proposed in the currently funded P01 was that androgen receptor (AR) remained an important driver in prostate cancer (PC) that becomes resistant to AR targeted therapies, and that adaptations made by tumor cells as they progress create new dependencies and…